Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
公司与泰达宏利基金管理有限公司签署之附条件生效的股份认购合同
Capital/Financing Update Classification · 95% confidence The document is a detailed contract titled '附条件生效的股份认购合同' (Conditional Share Subscription Agreement) between 江苏四环生物股份有限公司 and 泰达宏利基金管理有限公司. It outlines terms for a non-public issuance of shares, subscription price, payment terms, obligations of both parties, confidentiality, breach of contract, applicable law, and other contractual clauses. The content is a legal agreement related to a capital raising transaction involving share subscription. It is not an announcement, report, or presentation but a formal contract. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 4587 characters, sufficient for a full contract text rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2015-08-26 Chinese
关于召开2015年第二次临时股东大会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2015 second extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (both onsite and online), agenda items for shareholder approval, registration procedures, and voting instructions. The content focuses on the announcement and procedural details for the shareholders' meeting rather than the results of the meeting or the minutes. The document is not a report of voting results, nor is it a financial report or management discussion. It is a formal notification to shareholders about the meeting and how to participate and vote. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2015-08-26 Chinese
江苏晨薇生态园科技有限公司与江苏春辉生态农林股份有限公司签署之附生效条件的资产收购合同之补充协议
M&A Activity Classification · 70% confidence The document is a supplementary agreement to an asset acquisition contract between two companies, detailing terms such as transaction price, asset evaluation, and conditions for the contract's effectiveness. It is a legal contract related to an asset purchase, not a financial report, regulatory filing, or announcement. It does not fit into categories like M&A filings (which are typically formal merger or acquisition announcements or tender offers), but rather is a contract supplement related to an asset acquisition. Given the available categories, the closest match is 'M&A Activity (TAR)' which covers announcements and documents related to merger proposals or takeover bids, including asset acquisitions. The document is not a full merger filing but is related to an asset acquisition agreement, so TAR is the best fit with moderate confidence due to the legal contract nature and asset acquisition context.
2015-08-26 Chinese
公司与陶永生签署之附条件生效的股份认购合同
Capital/Financing Update Classification · 95% confidence The document is a detailed contract titled '附条件生效的股份认购合同' (Conditional Share Subscription Agreement) between a company and an individual for a non-public issuance of shares. It includes terms about share subscription, pricing, payment, legal compliance, confidentiality, and dispute resolution. It is a legal contract related to a private placement or non-public share issuance, not a report or announcement of financial results or corporate governance changes. It does not contain financial statements, audit information, or meeting materials. It is not a regulatory filing or announcement but a contractual agreement for capital raising through share subscription. Therefore, the document best fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2015-08-26 Chinese
公司与江阴市新桥第一毛纺厂签署之附生效条件的股权转让合同之补充协议
Regulatory Filings Classification · 95% confidence The document contains only placeholder text and omitted pictures, with no substantive content or text. It is extremely short (228 characters) and does not contain any financial data, regulatory references, or report details. Therefore, it cannot be classified as a report or detailed filing. Given the lack of content, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous or non-informative filings.
2015-08-26 Chinese
独立董事关于非公开发行股票的评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性和评估定价的公允性的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding the fairness, independence, and reasonableness of the valuation and pricing of a non-public stock issuance transaction. It discusses the evaluation agencies' independence, assumptions, methods, and fairness of the pricing related to a private placement and asset purchase. The document does not contain financial statements or detailed financial results but rather an assessment and opinion on a specific transaction's valuation fairness. This type of document is typically related to capital raising or financing activities, specifically non-public issuance of shares. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not merely an announcement or certification, so it is not RPA or RNS.
2015-08-26 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.